Home » Health » Johnson & Johnson Reveals Corona Vaccine Phase III Clinical Trial Results: 66% Efficacy

Johnson & Johnson Reveals Corona Vaccine Phase III Clinical Trial Results: 66% Efficacy

Meanwhile, Johnson & Johnson’s COVID-19 vaccine candidate also demonstrated complete protection against hospitalization and death 28 days after vaccination. There was a clear effect of the vaccine against cases of COVID-19 requiring medical intervention (hospitalization, ICU admission, mechanical ventilation, extracorporeal membrane oxygenation (ECMO)), with no cases reported from participants who received the vaccine 28 days after vaccination.

– .

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.